FAM111 trypsin like peptidase BGenealiases: CANP · POIKTMP
Q-omics provides the consensus-scored FAM111B profile across patient tissues and cancer cell-line models. FAM111B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FAM111B is differentially expressed in 17, with the highest sampling consensus in BLCA. Additionally, FAM111B RNA expression shows 19,537 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, BLCA, and UVM as cancer lineages where FAM111B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM111B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM111B survival associations across molecular data types. FAM111B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM111B RNA expression–survival associations across cancer types. High FAM111B expression shows unfavorable associations in ACC, KIRP, MESO, KICH, LIHC and PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FAM111B RNA expression.
This table summarizes FAM111B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for FAM111B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM111B shows higher tumor expression in BLCA, KIRC, HNSC, KIRP, THCA and COAD. The BLCA box plot shows higher FAM111B RNA expression in tumor versus normal tissue (log2 FC = +2.918, t-test p < 0.001).
This table shows molecular features associated with FAM111B in patient tissues and cancer cell lines. In patient samples, FAM111B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM111B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
